Sanofi accelerates Russian expansion

Sanofi (Euronext: SAN) is accelerating its Russian expansion by the recent launch of the production of its basal insulin Toujeo (insulin glargine) Solostar at the facilities of the French pharma major’s Sanofi Aventis Vostok plant, which is located in the Oryel region, according to the company.

The launch of the new production became part of a special investment contract signed by the company with the authorities of the Oryel region and the Russian Ministry of Industry and Trade in 2017, which involved the supplies of the company’s branded insulins for the needs of patients with diabetes in Russia.

The majority of the production is supplied to the domestic market; however, part of the output is also delivered to the European Union region. In recent years, the beginning of supplies of drugs produced in Russia to the EU market has become one of the most promising business directions for both Sanofi and other global pharmaceutical majors operating in the Russian market.